DNA plasmid vaccine ITI-1001
Term · Oncology and biomedicine · MLC-T-ONC-013095
An off-the-shelf (OTS) plasmid DNA cancer vaccine containing two DNA plasmids, one encoding for the two human cytomegalovirus (CMV) antigens immediate-early 1 (IE-1) and the matrix protein pp65 (65 kDa lower matrix phosphoprotein; UL83) fused to the lysosome-associated membrane protein 1 (LAMP-1), and one plasmid encoding for the CMV glycoprotein B (gB) antigen which is also fused to LAMP-1, with potential immunomodulating and antineoplastic activities, Upon intramuscular (IM) administration and following electroporation, the DNA plasmid vaccine ITI-1001 is taken up by antigen presenting cells (APCs) and transported via LAMP-1 and the lysosome-mediated pathway. This results in enhanced major histocompatibility (MHC) class II antigen presentation of the three antigens to the immune system, thereby promoting CD4-positive T-cell responses as well as CD8-positive T-cell responses against tumor cells expressing the three viral antigens. IE1, pp65 and gB are expressed in certain tumor types. The incorporation of LAMP-1 routes the CMV antigens into the lysosomal compartment.
| Identifier | MLC-T-ONC-013095 |
|---|---|
| Field | Oncology and biomedicine |
| Synonyms | CMV antigens vaccine ITI-1001; DNA vaccine ITI-1001; IE-1/pp65/gB-encoding pDNA vaccine ITI-1001; pDNA Vaccine ITI-1001 |
| References | National Cancer Institute Thesaurus (CC BY 4.0) |
Record as JSON
{
"id": "MLC-T-ONC-013095",
"term": "DNA plasmid vaccine ITI-1001",
"field": "Oncology and biomedicine",
"definition": "An off-the-shelf (OTS) plasmid DNA cancer vaccine containing two DNA plasmids, one encoding for the two human cytomegalovirus (CMV) antigens immediate-early 1 (IE-1) and the matrix protein pp65 (65 kDa lower matrix phosphoprotein; UL83) fused to the lysosome-associated membrane protein 1 (LAMP-1), and one plasmid encoding for the CMV glycoprotein B (gB) antigen which is also fused to LAMP-1, with potential immunomodulating and antineoplastic activities, Upon intramuscular (IM) administration and following electroporation, the DNA plasmid vaccine ITI-1001 is taken up by antigen presenting cells (APCs) and transported via LAMP-1 and the lysosome-mediated pathway. This results in enhanced major histocompatibility (MHC) class II antigen presentation of the three antigens to the immune system, thereby promoting CD4-positive T-cell responses as well as CD8-positive T-cell responses against tumor cells expressing the three viral antigens. IE1, pp65 and gB are expressed in certain tumor types. The incorporation of LAMP-1 routes the CMV antigens into the lysosomal compartment.",
"synonyms": [
"CMV antigens vaccine ITI-1001",
"DNA vaccine ITI-1001",
"IE-1/pp65/gB-encoding pDNA vaccine ITI-1001",
"pDNA Vaccine ITI-1001"
],
"references": [
"National Cancer Institute Thesaurus"
],
"url": "https://mlchart.com/terminology/oncology/dna-plasmid-vaccine-iti-1001/"
}
Record 6,112 of 17,721 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.